The Christie Charity
First Author Publications
Waddell T, Moorcraft SY, Cunningham D ‘Drug Evaluation: Potential role of rilotumumab in the treatment of gastric cancer’ Immunotherapy 2014; 6 (12): 1243-1253
Waddell T ‘Targeting EGFR in colorectal cancer: beyond KRAS exon 2’ Lancet Oncol 2014; 15 (6): 540-541
Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D ‘Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up’ Ann Oncol 2013; 24 (Suppl 6): vi57-63 (simultaneously published in Eur J Surg Oncol and Radiother Oncol)
Waddell T, Chau I, Cunningham D et al ‘Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial’ Lancet Oncol 2013; 14 (6): 481-489
Waddell T, Cunningham D ‘Evaluation of regorafenib in colorectal cancer and GIST’ Lancet 2013; 381 (9863): 273-275
Waddell T, Cunningham D ‘Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours’ Br J Surg 2013; 100 (1): 5-14
Waddell TS, Cunningham D ‘Chemotherapy: perioperative therapy improves gastroesophageal cancer survival’ Nat Rev Clin Oncol 2011; 7; 8(8): 450-452
Waddell T, Kotsori A, Constantinidou A et al ‘Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience’ Br J Cancer 2011; 104(11): 1675-1679
Waddell T, Gollins S, Soe W et al ‘Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study’ Canc Chemother and Pharmacol 2011; 67 (5): 1111-1117
Waddell T, Saunders M ‘Conference report: world congress on gastrointestinal cancer (WCGIC) 2008’ GI Canc Abstr 2008; 23: 2-4
Waddell TS, Hislop WS ‘Analysis of alcohol-related admissions in gastroenterology, cardiology and respiratory medicine’ Scot Med J 2003; 48: 114-116
Other Publications
Grenader T, Waddell T, Peckitt C et al ‘Prognostic value of neutrophil to lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial’ Ann Oncol 2016; epub ahead of print
Moorcraft SY, Fontana E, Cunningham D et al ‘Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study’ BMC Cancer 2016; 16: 112
Fontana E, Smyth EC, Cunningham D et al ‘Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010’ Gastric Cancer 2015; epub ahead of print
Smyth EC, Waddell TS, Cunningham D ‘Optimal management of oesophageal adenocarcinoma: should we be CROSS?’ J Clin Oncol 2014; 32 (27): 3080-1
Okines A, Gonzalez-de-Castro D, Cunningham D et al ‘Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials’ Eur J Canc 2013; 49 (9): 2116-2125
Okines A, Thompson L, Cunningham D et al ‘Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial’ Ann Oncol 2013; 24 (5): 1253-1261
Sheikh H, Valle J, Waddell T et al ‘Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer’ Br J Cancer 2008; 99: 577-583
Clarke R, Waddell T et al ‘A postcode lottery still exists for cancer patients with ‘exceptional circumstances’ Clin Onc 2008; 20 (10): 771-772